Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone443-545-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees350
OptionableOptionable
Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions
What is Osiris Therapeutics' stock symbol?
Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."
Has Osiris Therapeutics been receiving favorable news coverage?
Press coverage about OSIR stock has trended somewhat positive on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Osiris Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are some of Osiris Therapeutics' key competitors?
Some companies that are related to Osiris Therapeutics include Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD) and BioCryst Pharmaceuticals (BCRX).
Who are Osiris Therapeutics' key executives?
Osiris Therapeutics' management team includes the folowing people:
- Mr. Jason Keefer, Interim Pres & CEO (Age 46)
- Dr. Alla N. Danilkovitch, Chief Scientific Officer (Age 54)
- Mr. Joel David Rogers, Interim Chief Financial Officer (Age 56)
- Mr. Edward Yip, Chief Legal Officer & Corp. Sec.
- Mr. Laine Dyess, VP of Sales
Who are Osiris Therapeutics' major shareholders?
Osiris Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Gabelli Funds LLC (1.72%), Geode Capital Management LLC (0.36%), Northern Trust Corp (0.32%), Barclays PLC (0.10%), CAPROCK Group Inc. (0.10%) and Millennium Management LLC (0.10%). View Institutional Ownership Trends for Osiris Therapeutics.
Which major investors are selling Osiris Therapeutics stock?
Which major investors are buying Osiris Therapeutics stock?
OSIR stock was acquired by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Barclays PLC, CAPROCK Group Inc., Northern Trust Corp, Geode Capital Management LLC, Millennium Management LLC, BlackRock Inc. and Virtu Financial LLC. View Insider Buying and Selling for Osiris Therapeutics.
How do I buy shares of Osiris Therapeutics?
Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Osiris Therapeutics' stock price today?
One share of OSIR stock can currently be purchased for approximately $15.76.
How big of a company is Osiris Therapeutics?
Osiris Therapeutics has a market capitalization of $544.13 million. Osiris Therapeutics employs 350 workers across the globe.
What is Osiris Therapeutics' official website?
How can I contact Osiris Therapeutics?
Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]
MarketBeat Community Rating for Osiris Therapeutics (OTCMKTS OSIR)
MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe OSIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSIR will underperform the S&P 500 over the long term. You may vote once every thirty days.
